{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:57:25Z","timestamp":1790521045780,"version":"4.1.0"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2010,12,15]],"date-time":"2010-12-15T00:00:00Z","timestamp":1292371200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0015337","type":"journal-article","created":{"date-parts":[[2010,12,15]],"date-time":"2010-12-15T20:59:35Z","timestamp":1292446775000},"page":"e15337","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":72,"title":["Prescription Drugs Associated with Reports of Violence Towards Others"],"prefix":"10.1371","volume":"5","author":[{"given":"Thomas J.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Glenmullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curt D.","family":"Furberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2010,12,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/cap.2006.16.33","article-title":"Postmarketing surveillance of suicidal adverse events with pediatric use of antidepressants.","volume":"16","author":"AD Mosholder","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/cap.2006.16.25","article-title":"Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressant drugs are associated with active drug treatment: a meta-analysis.","volume":"16","author":"AD Mosholder","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref3","article-title":"CHANTIX (varenicline tartrate) tablet, film coated [package insert].","year":"2010"},{"key":"ref4","article-title":"AMBIEN (zolpidem tartrate) tablet, film coated [package insert].","year":"2009"},{"key":"ref5","article-title":"SINGULAIR (montelukast sodium) tablet, film coated [package insert].","year":"2010"},{"key":"ref6","article-title":"New Warnings Proposed for Antidepressants.","year":"2007"},{"key":"ref7","article-title":"PAXIL (paroxetine hydrochloride) tablet, film coated [package insert].","year":"2009"},{"key":"ref8","article-title":"ZOLOFT (sertraline hydrochloride) tablet, film coated [package insert].","year":"2008"},{"key":"ref9","article-title":"SEROQUEL (quetiapine fumarate) tablet, film coated [package insert].","year":"2010"},{"key":"ref10","article-title":"QuarterWatch: 2008 Quarter 1.","author":"T Moore","year":"2008"},{"key":"ref11","article-title":"The Adverse Event Reporting System (AERS): Latest Quarterly Data File.","year":"2010"},{"key":"ref12","article-title":"Unified Medical Language System (UMLS): RxNorm.","year":"2010"},{"key":"ref13","article-title":"Introductory Guide: MedDRA Version 12.1.","year":"2009"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.","volume":"10","author":"SJ Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref15","article-title":"QuarterWatch: 2009 Quarter 4.","author":"TJ Moore","year":"2010"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1021\/jm050069n","article-title":"Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.","volume":"48","author":"JW Coe","year":"2005","journal-title":"J Med Chem"},{"key":"ref17","article-title":"XYREM (sodium oxybate) solution [package insert].","year":"2009"},{"key":"ref18","article-title":"Goodman & Gilman's the Pharmacological Basis of Therapeutics.","author":"LS Goodman","year":"2001"},{"key":"ref19","first-page":"199","article-title":"Varenicline: a British review. Unfavorable risk-benefit balance.","volume":"17","year":"2008","journal-title":"Prescrire Int"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"b4964","DOI":"10.1136\/bmj.b4964","article-title":"Varenicline and suicide. Risk of psychiatric side effects with varenicline.","volume":"339","author":"TJ Moore","year":"2009","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1345\/aph.1P172","article-title":"Thoughts and acts of aggression\/violence toward others reported in association with varenicline.","volume":"44","author":"TJ Moore","year":"2010","journal-title":"Ann Pharmacother"},{"key":"ref22","article-title":"Strong Signal Seen for New Varenicline Risks.","author":"TJ Moore","year":"2008"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0015337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T02:24:58Z","timestamp":1588991098000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0015337"}},"subtitle":[],"editor":[{"given":"Joseph S.","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,12,15]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2010,12,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0015337","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,15]]}}}